DNAprint Genomics (DNAG)

[frogdreaming]

If I remember the CMIH scenario correctly. (which is doubtful)
DNAP would run an analysis on a set of samples, provided and sorted by the customer, and provide classifier markers from the data for about $100,000.00.

(I think CMIH was going to obtain samples from African-Americans and try to extract (cancer?) data.)

Given this service, and the proposed scenario of a drug company that has run into a compatability issue in the late stages of development, what would make more sense to the drug company?

Take the DNA samples from the test subjects and hire DNAP to run an analysis to determine the appropriate classifier markers, or sell the drug and the sample data to DNAP for a fraction of it's eventual value?

$100K would seem like a pittance in comparison to the millions required for multistage testing.

Did the CMIH deal provide any downstream income to DNAP or was it just limited to the up front fee?

I'm just trying to assess the likelihood that DNAP will have access to such drug targets.

regards,
frog